Latest filing published 27 Apr 2026 for Insight Molecular Diagnostics Inc.. Read the official filing
Across 60 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Broadwood Partners, L.P. has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Staar Surgical Co, Insight Molecular Diagnostics Inc. and Lineage Cell Therapeutics, Inc. In total, 114 filings cover trades dated from 30 December 2015 to 27 April 2026.
Market trades split into 107 purchases (€82.5M) and 4 sales (€18.6M). The amount is not disclosed for 64 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant. 2026 to date brings 17 purchases and no sales.
The median purchase comes to €1.1M. Clusters matter here: 9 out of 95 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The record was last updated on 27 April 2026 with an open-market purchase (€841k) in Insight Molecular Diagnostics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 114 declarations